Cancer News and Research

Latest Cancer News and Research

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

Viewpoints: Confronting 'giant' Medicare choices; first lady's anti-obesity campaign; Calif. insurance rules

Sometimes life presents you with a basic philosophical choice. Americans are going to have to confront a giant one over the next several years. It starts in the wonky world of Medicare. ... Democrats have much greater faith in centralized expertise. ... [Republicans] have much greater faith in the decentralized discovery process of the market.

8 Jun 2011

$Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS$

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik, Inc. today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome.

8 Jun 2011

Clinical-research expert moving to Stanford

Steven Goodman, MD, PhD, has worn many hats through his long and varied career, from pediatrician to biostatistician, from epidemiologist to clinical trial expert, from scientist to, well, opera singer. Admittedly, opera has been more of a hobby for him than a career path, but it does give some indication of his ability to master a wide range of subjects.

7 Jun 2011

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Cyterix Pharmaceutics, Inc. announced today that the company has raised $9.2 million in a Series A financing from The Column Group and SV Life Sciences. Cyterix is developing novel cancer therapeutics based on a prodrug approach that targets extra-hepatic cytochrome P450 enzymes that are over-expressed in many cancers to a high frequency, but not in normal tissues.

7 Jun 2011

Smoking increases woman's risk for peripheral artery disease 10-fold

A prospective study of initially healthy women aged 45 and over found that smoking is a potent risk factor for symptomatic peripheral artery disease, or PAD. PAD is a serious, often debilitating disorder, caused by narrowing of the arteries in the lower extremities. Symptoms of PAD include pain in the legs with normal activity and a feeling of tiredness in the leg muscles.

7 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

7 Jun 2011

Merck, Roche partner to develop cancer diagnostic assays

Merck, known outside the United States and Canada as MSD, and Roche today announced that they have entered into a collaboration focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio.

From Roche Sequencing and Life Science 7 Jun 2011

IsoRay completes Iotrex license agreement with Dr. Reddy's

IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.

7 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that a settlement agreement with certain former shareholders and directors of Jiangsu Quanyi Biological Technology Stock Co., Ltd. has become effective.

7 Jun 2011

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

DxTerity Diagnostics announced today that it has acquired intellectual property rights to several blood based cancer diagnostic tests from SourceMDx Inc.

7 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Moving Met molecules from inside to outside of the cell could halt cancer growth

Work by researchers at Queen Mary, University of London could point to a new way to treat aggressive types of cancer.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

7 Jun 2011

Renewal Project receives Palo Alto City Council's certification to rebuild, expand Stanford Hospitals

The Palo Alto City Council today voted unanimously to certify the Final Environmental Impact Report (FEIR), grant land use approvals and execute a Development Agreement with Stanford Hospital & Clinics, Lucile Packard Children's Hospital and Stanford University, including a $175 million community benefits package as part of the Renewal Project.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Viewpoints: Confronting 'giant' Medicare choices; first lady's anti-obesity campaign; Calif. insurance rules

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Clinical-research expert moving to Stanford

Cyterix raises $9.2M in Series A financing from The Column Group and SV Life Sciences

Smoking increases woman's risk for peripheral artery disease 10-fold

LLS announces four new Academic Concierge partnerships for cancer drug development

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Merck, Roche partner to develop cancer diagnostic assays

IsoRay completes Iotrex license agreement with Dr. Reddy's

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Moving Met molecules from inside to outside of the cell could halt cancer growth

Unique clinical trial addresses important questions about treating AIDS-related cancers

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Renewal Project receives Palo Alto City Council's certification to rebuild, expand Stanford Hospitals

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in